Braidwell LP Makes New Investment in Surrozen, Inc. $SRZN

Braidwell LP purchased a new position in Surrozen, Inc. (NASDAQ:SRZN) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 140,000 shares of the company’s stock, valued at approximately $1,252,000.

Several other large investors also recently modified their holdings of SRZN. Stonepine Capital Management LLC raised its stake in Surrozen by 108.3% during the first quarter. Stonepine Capital Management LLC now owns 285,782 shares of the company’s stock worth $3,332,000 after buying an additional 148,582 shares during the last quarter. Heights Capital Management Inc. acquired a new stake in Surrozen during the 1st quarter worth about $524,000. Driehaus Capital Management LLC acquired a new stake in Surrozen during the 1st quarter worth about $2,390,000. Nantahala Capital Management LLC grew its holdings in Surrozen by 17.1% during the 1st quarter. Nantahala Capital Management LLC now owns 229,527 shares of the company’s stock worth $2,676,000 after acquiring an additional 33,504 shares during the period. Finally, RA Capital Management L.P. raised its position in shares of Surrozen by 140.3% in the 1st quarter. RA Capital Management L.P. now owns 679,130 shares of the company’s stock worth $7,919,000 after acquiring an additional 396,550 shares in the last quarter. 66.57% of the stock is currently owned by institutional investors and hedge funds.

Surrozen Price Performance

Shares of SRZN opened at $24.59 on Friday. Surrozen, Inc. has a one year low of $5.90 and a one year high of $24.94. The company has a market cap of $210.74 million, a PE ratio of -1.10 and a beta of 0.62. The stock has a 50-day moving average of $14.89 and a 200-day moving average of $11.80.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings results on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($2.44). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%.The firm had revenue of $0.98 million during the quarter. Analysts expect that Surrozen, Inc. will post -8.49 EPS for the current fiscal year.

Insiders Place Their Bets

In other Surrozen news, Director Tim Kutzkey purchased 315,457 shares of Surrozen stock in a transaction that occurred on Thursday, November 13th. The stock was acquired at an average price of $12.65 per share, with a total value of $3,990,531.05. Following the transaction, the director owned 962,718 shares in the company, valued at $12,178,382.70. This trade represents a 48.74% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Group Gp Lp Column III purchased 315,457 shares of the firm’s stock in a transaction on Thursday, November 13th. The shares were acquired at an average price of $12.65 per share, with a total value of $3,990,531.05. Following the purchase, the insider directly owned 962,718 shares in the company, valued at $12,178,382.70. This represents a 48.74% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders purchased 703,214 shares of company stock worth $9,370,739. 45.18% of the stock is owned by company insiders.

Analyst Ratings Changes

SRZN has been the topic of several research analyst reports. Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded Surrozen to a “sell” rating in a report on Friday, November 28th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Surrozen currently has an average rating of “Moderate Buy” and an average target price of $38.50.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.